Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression

Bioconjugate Chemistry

Volumn 26, Issue 8, 2015, Pages 1513-1518

  Kim, Eunha ^a   Yang, Katherine S ^a   Kohler, Rainer H ^a   Dubach, John M ^a   Mikula, Hannes ^a   Weissleder, Ralph ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DIAGNOSIS;

APOPTOTIC SIGNALING; BRUTON'S TYROSINE KINASE; FLUORESCENT AGENTS; FLUOROCHROMES; IN-VIVO; IN-VIVO IMAGING; INNATE IMMUNE RESPONSE; NEAR-IR; SIGNALLING PATHWAYS; TYROSINE KINASE INHIBITOR;

DISEASES;

BRUTON TYROSINE KINASE; FLUOROCHROME; IBRUTINIB; SPEBRUTINIB; AGAMMAGLOBULINAEMIA TYROSINE KINASE; FLUORESCENT DYE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; CARBOXYLATION; DRUG CONJUGATION; DRUG SYNTHESIS; IC50; IMAGING; IN VIVO STUDY; INFRARED SPECTROSCOPY; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; B LYMPHOCYTE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; FIBROSARCOMA; HUMAN; MOLECULAR IMAGING; NEAR INFRARED SPECTROSCOPY; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

APOPTOSIS; B-LYMPHOCYTES; FIBROSARCOMA; FLUORESCENT DYES; HUMANS; MOLECULAR IMAGING; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SPECTROSCOPY, NEAR-INFRARED; T-LYMPHOCYTES;

EID: 84939809284     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00152     Document Type: Article

References (35)

1. de Weers, M., Brouns, G. S., Hinshelwood, S., Kinnon, C., Schuurman, R. K., Hendriks, R. W., and Borst, J. (1994) B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia J. Biol. Chem. 269, 23857-23860
2. Rawlings, D. J., Saffran, D. C., Tsukada, S., Largaespada, D. A., Grimaldi, J. C., Cohen, L., Mohr, R. N., Bazan, J. F., Howard, M., and Copeland, N. G. et al. 1993, Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice Science 261, 358-361
3. Kawakami, Y., Kitaura, J., Hartman, S. E., Lowell, C. A., Siraganian, R. P., and Kawakami, T. (2000) Regulation of protein kinase CβI by two protein-tyrosine kinases, Btk and Syk Proc. Natl. Acad. Sci. U.S.A. 97, 7423-7428
4. Gray, P., Dunne, A., Brikos, C., Jefferies, C. A., Doyle, S. L., and O'Neill, L. A. (2006) MyD88 Adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction J. Biol. Chem. 281, 10489-10495
5. Liljeroos, M., Vuolteenaho, R., Morath, S., Hartung, T., Hallman, M., and Ojaniemi, M. (2007) Bruton's tyrosine kinase together with PI 3-kinase are part of Toll-like receptor 2 multiprotein complex and mediate LTA induced Toll-like receptor 2 responses in macrophages Cell. Signal. 19, 625-633
6. Vassilev, A., Ozer, Z., Navara, C., Mahajan, S., and Uckun, F. M. (1999) Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex J. Biol. Chem. 274, 1646-1656
7. Tai, Y. T. and Anderson, K. C. (2012) Bruton's tyrosine kinase: oncotarget in myeloma Oncotarget 3, 913-914
8. Rushworth, S. A., Murray, M. Y., Zaitseva, L., Bowles, K. M., and MacEwan, D. J. (2014) Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia Blood 123, 1229-1238
9. Woyach, J. A., Bojnik, E., Ruppert, A. S., Stefanovski, M. R., Goettl, V. M., Smucker, K. A., Smith, L. L., Dubovsky, J. A., Towns, W. H., and MacMurray, J. et al. 2014, Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL) Blood 123, 1207-1213
10. Bogusz, A. M., Baxter, R. H., Currie, T., Sinha, P., Sohani, A. R., Kutok, J. L., and Rodig, S. J. (2012) Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma Clin. Cancer. Res. 18, 6122-6135
11. Cinar, M., Hamedani, F., Mo, Z., Cinar, B., Amin, H. M., and Alkan, S. (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis Leuk. Res. 37, 1271-1277
12. Ni Gabhann, J., Hams, E., Smith, S., Wynne, C., Byrne, J. C., Brennan, K., Spence, S., Kissenpfennig, A., Johnston, J. A., and Fallon, P. G. et al. 2014, Btk regulates macrophage polarization in response to lipopolysaccharide PLoS One 9, e85834
13. Feng, M., Chen, J. Y., Weissman-Tsukamoto, R., Volkmer, J. P., Ho, P. Y., McKenna, K. M., Cheshier, S., Zhang, M., Guo, N., and Gip, P. et al. 2015, Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk Proc. Natl. Acad. Sci. U.S.A. 112, 2145-2150
14. Herbst, S., Shah, A., Mazon Moya, M., Marzola, V., Jensen, B., Reed, A., Birrell, M. A., Saijo, S., Mostowy, S., and Shaunak, S. et al. 2015, Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus EMBO Mol. Med. 7, 240-258
15. Ruffell, B., Affara, N. I., and Coussens, L. M. (2012) Differential macrophage programming in the tumor microenvironment Trends Immunol. 33, 119-126
16. Hao, N. B., Lu, M. H., Fan, Y. H., Cao, Y. L., Zhang, Z. R., and Yang, S. M. (2012) Macrophages in tumor microenvironments and the progression of tumors Clin. Dev. Immunol. 2012, 948098
17. Kinne, R. W., Brauer, R., Stuhlmuller, B., Palombo-Kinne, E., and Burmester, G. R. (2000) Macrophages in rheumatoid arthritis Arthritis Res. 2, 189-202
18. Hartkamp, L. M., Fine, J. S., van Es, I. E., Tang, M. W., Smith, M., Woods, J., Narula, S., Demartino, J., Tak, P. P., and Reedquist, K. A. (2014) Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Ann. Rheum. Dis. DOI: 10.1136/annrheumdis-2013-204143.
19. Zhou, P., Ma, B., Xu, S., Zhang, S., Tang, H., Zhu, S., Xiao, S., Ben, D., and Xia, Z. (2014) Knockdown of Burton's tyrosine kinase confers potent protection against sepsis-induced acute lung injury Cell Biochem. Biophys. 70, 1265-1275
20. Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., and Chang, B. Y. et al. 2013, Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies J. Clin. Oncol. 31, 88-94
21. Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., and Wierda, W. G. et al. 2013, Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia N. Engl. J. Med. 369, 32-42
22. Evans, E. K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M. T., Witowski, S. R., Lounsbury, H., Chaturvedi, P., and Mazdiyasni, H. et al. 2013, Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans J. Pharmacol. Exp. Ther. 346, 219-228
23. Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., and Williams, M. E. et al. 2013, Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma N. Engl. J. Med. 369, 507-516
24. Lou, Y., Owens, T. D., Kuglstatter, A., Kondru, R. K., and Goldstein, D. M. (2012) Bruton's tyrosine kinase inhibitors: Approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies J. Med. Chem. 55, 4539-4550
25. Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., and Miller, R. A. et al. 2010, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U.S.A. 107, 13075-13080
26. Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., and Gray, N. S. (2013) Developing irreversible inhibitors of the protein kinase cysteinome Chem. Biol. 20, 146-159
27. Turetsky, A., Kim, E., Kohler, R. H., Miller, M. A., and Weissleder, R. (2014) Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor Sci. Rep. 4, 4782
28. Koide, Y., Urano, Y., Hanaoka, K., Piao, W., Kusakabe, M., Saito, N., Terai, T., Okabe, T., and Nagano, T. (2012) Development of NIR fluorescent dyes based on Si-rhodamine for in vivo imaging J. Am. Chem. Soc. 134, 5029-5031
29. Srinivasarao, M., Galliford, C. V., and Low, P. S. (2015) Principles in the design of ligand-targeted cancer therapeutics and imaging agents Nat. Rev. Drug Discovery 14, 203-219
30. Lanning, B. R., Whitby, L. R., Dix, M. M., Douhan, J., Gilbert, A. M., Hett, E. C., Johnson, T. O., Joslyn, C., Kath, J. C., and Niessen, S. et al. 2014, A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors Nat. Chem. Biol. 10, 760-767
31. Zhang, Q., Liu, H., and Pan, Z. (2014) A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells Chem. Commun. (Cambridge) 50, 15319-15322
32. Kim, E., Yang, K. S., Giedt, R. J., and Weissleder, R. (2014) Red Si-rhodamine drug conjugates enable imaging in GFP cells Chem. Commun. (Cambridge) 50, 4504-4507
33. Choi, H. S., Nasr, K., Alyabyev, S., Feith, D., Lee, J. H., Kim, S. H., Ashitate, Y., Hyun, H., Patonay, G., and Strekowski, L. et al. 2011, Synthesis and In Vivo Fate of Zwitterionic Near-Infrared Fluorophores Angew. Chem., Int. Ed. 50, 6258-6263
34. Grimm, J. B., English, B. P., Chen, J., Slaughter, J. P., Zhang, Z., Revyakin, A., Patel, R., Macklin, J. J., Normanno, D., and Singer, R. H. et al. 2015, A general method to improve fluorophores for live-cell and single-molecule microscopy Nat. Methods 12, 244-250
35. Lukinavicius, G., Umezawa, K., Olivier, N., Honigmann, A., Yang, G., Plass, T., Mueller, V., Reymond, L., Correa, I. R. J., and Luo, Z. G. et al. 2013, A near-infrared fluorophore for live-cell super-resolution microscopy of cellular proteins Nat. Chem. 5, 132-139